What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Jordan EJ, Kim HR, Arcila ME, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017 Jun;7(6):596–609. doi: 10.1158/2159-8290.CD-16-1337
   PubMed Web of Science ®Google Scholar
• Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021 Oct;18(10):625–644. doi: 10.1038/s41571-021-00520-1
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021 Jun;18(6):345–362. doi: 10.1038/s41571-021-00473-5
   PubMed Web of Science ®Google Scholar
• Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021 Feb 13;397(10274):592–604. doi: 10.1016/S0140-6736(21)00228-2
   PubMed Web of Science ®Google Scholar
• Rehman JA, Han G, Carvajal-Hausdorf DE, et al. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Mod Pathol. 2017 Mar;30(3):340–349. doi: 10.1038/modpathol.2016.186
   PubMed Web of Science ®Google Scholar
• Munari E, Zamboni G, Lunardi G, et al. PD-L1 expression heterogeneity in non–small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections. J Thorac Oncol. 2018 Aug 1;13(8):1113–1120. doi: 10.1016/j.jtho.2018.04.017
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Aubry MC, Moser JC, et al. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016 Oct 1;27(10):1953–1958. doi: 10.1093/annonc/mdw289
   PubMed Web of Science ®Google Scholar
• Wu J, Sun W, Yang X, et al. Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer. Mod Pathol. 2022 Feb;35(2):218–227. doi: 10.1038/s41379-021-00903-w
   PubMed Web of Science ®Google Scholar
• Ricciuti B, Wang X, Alessi JV, et al. Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022 Aug;8(8):1160–1168. doi: 10.1001/jamaoncol.2022.1981
   PubMed Web of Science ®Google Scholar
• Research C for DE and. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. 2020 Jun 17 [cited 2021 Aug 22]; Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors
   Google Scholar
• Pizzutilo EG, Romanò R, Roazzi L, et al. Immune checkpoint inhibitors and the exposome: host-extrinsic factors determine response, survival, and toxicity. Cancer Res. 2023 Jul 14;83(14):2283–2296. doi: 10.1158/0008-5472.CAN-23-0161
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez–Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-Cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019 Mar;37(7):537–546. doi: 10.1200/JCO.18.00149
   PubMed Web of Science ®Google Scholar
• Jassem J, de MF, Giaccone G, et al. Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1–selected NSCLC. J Thorac Oncol. 2021 Nov 1;16(11):1872–1882. doi: 10.1016/j.jtho.2021.06.019
   PubMed Web of Science ®Google Scholar
• Rosell R, Gonzalez-Cao M. Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer. Lancet. 2021 Feb 13;397(10274):557–559. doi: 10.1016/S0140-6736(21)00196-3
   PubMed Web of Science ®Google Scholar
• Cochrane database of systematic reviews: all issues | cochrane library [internet]. [cited 2022 Oct 7]. Available from: https://www.cochranelibrary.com/cdsr/table-of-contents?volume=2020&issue=12
   Google Scholar
• Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for Previously untreated metastatic nonsquamous non–small-Cell lung cancer. J Clin Oncol. 2020 May 10;38(14):1505–1517. doi: 10.1200/JCO.19.03136
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Vicente D, Tafreshi A, et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. Journal Of Thoracic Oncology. 2020 Oct;15(10):1657–1669. doi: 10.1016/j.jtho.2020.06.015
   PubMed Web of Science ®Google Scholar
• West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul 1;20(7):924–937. doi: 10.1016/S1470-2045(19)30167-6
   PubMed Web of Science ®Google Scholar
• Socinski MA, Nishio M, Jotte RM, et al. IMpower150 final overall survival analyses for atezolizumab plus Bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021 Nov 1;16(11):1909–1924. doi: 10.1016/j.jtho.2021.07.009
   PubMed Web of Science ®Google Scholar
• Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019 Aug;30(8):1321–1328. doi: 10.1093/annonc/mdz167
   PubMed Web of Science ®Google Scholar
• Dudnik E, Peled N, Nechushtan H, et al. BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors. J Thorac Oncol. 2018 Aug 1;13(8):1128–1137. doi: 10.1016/j.jtho.2018.04.024
   PubMed Web of Science ®Google Scholar
• Schoenfeld AJ, Rizvi H, Bandlamudi C, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol Off J Eur Soc Med Oncol. 2020 May;31(5):599–608. doi: 10.1016/j.annonc.2020.01.065
   PubMed Web of Science ®Google Scholar
• Hendriks LE, Kerr KM, Menis J, et al. Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up†. Ann Oncol. 2023 Jan 17 [cited 2023 Jan 17];34(4). InternetAvailable from https://www.annalsofoncology.org/article/S0923-7534(22)04785-8/fulltext
   Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-Cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020–2031. doi: 10.1056/NEJMoa1910231
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020 May 1;6(5):661–674. doi: 10.1001/jamaoncol.2020.0237
   PubMed Web of Science ®Google Scholar
• Boyer M, Şendur MAN, Rodríguez-Abreu D, et al. Pembrolizumab plus ipilimumab or placebo for metastatic non–small-Cell lung cancer with PD-L1 tumor proportion score ≥ 50%: randomized, double-blind phase III KEYNOTE-598 study. J Clin Oncol. 2021 Jul 20;39(21):2327–2338. doi: 10.1200/JCO.20.03579
   PubMed Web of Science ®Google Scholar
• Research C for DE and. FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%). FDA [Internet]. 2021 Nov 6 [cited 2023 Jan 17]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1
   Google Scholar
• Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb 1;22(2):198–211. doi: 10.1016/S1470-2045(20)30641-0
   PubMed Web of Science ®Google Scholar
• Schoenfeld AJ, Antonia SJ, Awad MM, et al. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann Oncol. 2021 Dec 1;32(12):1597–1607. doi: 10.1016/j.annonc.2021.08.2151
   PubMed Web of Science ®Google Scholar
• Kluger HM, Tawbi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce. J Immunother Cancer. 2020 Mar 1;8(1):e000398. doi: 10.1136/jitc-2019-000398
   PubMed Web of Science ®Google Scholar
• Wang F, Wang S, Zhou Q. The resistance mechanisms of lung cancer immunotherapy. Front Oncol. InternetAvailable from. 2020 cited 2022 Oct 8;10. doi: 10.3389/fonc.2020.568059
   Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-Cell lung cancer with PD-L1 tumor proportion score ≥ 50%. J Clin Oncol. 2021 Jul 20;39(21):2339–2349. doi: 10.1200/JCO.21.00174
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non–small-Cell lung cancer. N Engl J Med. 2017 Jun 22;376(25):2415–2426. doi: 10.1056/NEJMoa1613493
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819–1830. doi: 10.1016/S0140-6736(18)32409-7
   PubMed Web of Science ®Google Scholar
• Velcheti V, Hu X, Yang L, et al. Long-term real-world outcomes of first-line pembrolizumab monotherapy for metastatic non-small cell lung cancer with ≥50% expression of programmed cell death-ligand 1. Front Oncol. Internet. 2022 cited 2022 Oct 8;12. doi: 10.3389/fonc.2022.834761.
   Web of Science ®Google Scholar
• Waterhouse D, Lam J, Betts KA, et al. Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer. Lung Cancer. 2021 Jun 1;156:41–49. doi: 10.1016/j.lungcan.2021.04.007
   PubMed Web of Science ®Google Scholar
• Bersanelli M, Buti S, Giannarelli D, et al. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: the multicenter retrospective CLARITY study. Lung Cancer. 2020 Dec 1;150:123–131. doi: 10.1016/j.lungcan.2020.10.008
   PubMed Web of Science ®Google Scholar
• Cortellini A, Cannita K, Tiseo M, et al. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. Eur J Cancer. 2021 May 1;148:24–35. doi: 10.1016/j.ejca.2021.02.005
   PubMed Web of Science ®Google Scholar
• Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol. 2020 Aug 1;15(8):1351–1360. doi: 10.1016/j.jtho.2020.03.028
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, Ramalingam SS, Ciuleanu TE, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol. 2022 Feb 1;17(2):289–308. doi: 10.1016/j.jtho.2021.09.010
   PubMed Web of Science ®Google Scholar
• Leighl NB, Laurie SA, Goss GD, et al. CCTG BR34: a randomized phase 2 trial of durvalumab and tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC. J Thorac Oncol. 2022 Mar 1;17(3):434–445. doi: 10.1016/j.jtho.2021.10.023
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non–small-Cell lung cancer Previously treated with platinum-based chemotherapy. J Clin Oncol. 2000 May 10;18(10):2095–2103. doi: 10.1200/JCO.2000.18.10.2095
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non–small-Cell lung cancer Previously treated with chemotherapy. J Clin Oncol. 2004 May;22(9):1589–1597. doi: 10.1200/JCO.2004.08.163
   PubMed Web of Science ®Google Scholar
• Hotta K, Fujiwara Y, Kiura K, et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol. 2007 May 1;2(5):402–407. doi: 10.1097/01.JTO.0000268673.95119.c7
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in Previously treated non–small-Cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123–132. doi: 10.1056/NEJMoa050753
   PubMed Web of Science ®Google Scholar
• Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013 Sep 1;14(10):981–988. doi: 10.1016/S1470-2045(13)70310-3
   PubMed Web of Science ®Google Scholar
• Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non–small-Cell lung cancer. J Clin Oncol. 2009 Apr 10;27(11):1836–1843. doi: 10.1200/JCO.2008.17.5844
   PubMed Web of Science ®Google Scholar
• Reinhorn D, Jacobi O, Icht O, et al. Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer. Immunotherapy. 2020 Mar;12(4):235–243. doi: 10.2217/imt-2019-0131
   PubMed Web of Science ®Google Scholar
• Zhang B, Bowerman NA, Salama JK, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007 Jan 22;204(1):49–55. doi: 10.1084/jem.20062056
   PubMed Web of Science ®Google Scholar
• Park SE, Lee SH, Ahn JS, et al. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non–small cell lung cancer. J Thorac Oncol. 2018 Jan 1;13(1):106–111. doi: 10.1016/j.jtho.2017.10.011
   PubMed Web of Science ®Google Scholar
• Schvartsman G, Peng SA, Bis G, et al. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2017 Oct 1;112:90–95. doi: 10.1016/j.lungcan.2017.07.034
   PubMed Web of Science ®Google Scholar
• Kato R, Hayashi H, Chiba Y, et al. Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L). J Immunother Cancer. 2020 Feb 16;8(1):e000350. doi: 10.1136/jitc-2019-000350
   PubMed Web of Science ®Google Scholar
• Metro G, Addeo A, Signorelli D. et al. Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort. J Thorac Dis. Internet. 2019 Dec [cited 2022 Sep 22];11(12):4972–4981. doi: 10.21037/jtd.2019.12.23
   PubMed Web of Science ®Google Scholar
• Liu S, Hu X, Chirovsky D, et al. OA07.04 overall survival in patients with advanced NSCLC receiving taxane-containing regimen after exposure to immunotherapy and platinum-doublet. J Thorac Oncol. 2022 Sep 1;17(9, Supplement):S21. doi: 10.1016/j.jtho.2022.07.041
   Web of Science ®Google Scholar
• Camidge DR, Karve S, Xu Q, et al. 1126P - Project LUMINATE-101: real-world outcomes of EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (aNSCLC) patients receiving docetaxel post frontline (1L) platinum-based chemotherapy in combination with pembrolizumab. ESMO Congress 2022.
   Google Scholar
• Auclin E, Benitez-Montanez J, Gorria T, et al. OA07.06 second line treatment outcomes after progression on immunotherapy plus chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC). IASLC 2022 World Conference on Lung Cancer | Vienna, Austria.
   Google Scholar
• Jung HA, Park S, Choi YL, et al. Continuation of pembrolizumab with additional chemotherapy after progression with PD-1/PD-L1 inhibitor monotherapy in patients with advanced NSCLC: a randomized, placebo-controlled phase II study. Clin Cancer Res. 2022 Jun 1;28(11):2321–2328. doi: 10.1158/1078-0432.CCR-21-3646
   PubMed Web of Science ®Google Scholar
• Ozguroglu M, Kilickap S, Sezer A, et al. LBA54 - three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): the EMPOWER-Lung 1 trial. ESMO Congress; Paris; 2022.
   Google Scholar
• National Cancer Institute (NCI). EA5163/S1709 INSIGNA: a randomized, phase III study of firstline immunotherapy alone or in combination with chemotherapy in induction/maintenance or postprogression in advanced Nonsquamous non-small cell lung cancer (NSCLC) with Immunobiomarker SIGNature-Driven analysis [internet]. clinicaltrials.gov; 2022 Oct [cited 2022 Oct 9]. Report No.: NCT03793179. Available from: https://clinicaltrials.gov/ct2/show/NCT03793179
   Google Scholar
• Paz-Ares L, Goto Y, Lim WDT, et al. 1194MO canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results. Ann Oncol. 2021 Sep 1;32:S953–4. doi: 10.1016/j.annonc.2021.08.1799
   Google Scholar
• Ishikura N, Sugimoto M, Yorozu K, et al. Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1low and immune desert-like mouse tumors. Oncol Rep. 2022 Feb;47(2):36. doi: 10.3892/or.2021.8247
   PubMed Web of Science ®Google Scholar
• Horvath L, Thienpont B, Zhao L, et al. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. Mol Cancer. 2020 Sep 11;19(1):141. doi: 10.1186/s12943-020-01260-z
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Aug 23;384(9944):665–673. doi: 10.1016/S0140-6736(14)60845-X
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014 Feb 1;15(2):143–155. doi: 10.1016/S1470-2045(13)70586-2
   PubMed Web of Science ®Google Scholar
• Remon J, Lacas B, Herbst R, et al. Antiangiogenic second-line lung cancer meta-analysis on individual patient data in non-small cell lung cancer: ANSELMA. Eur J Cancer. 2022 May 1;166:112–125. doi: 10.1016/j.ejca.2022.02.002
   PubMed Web of Science ®Google Scholar
• Molife C, Hess LM, Cui ZL, et al. Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice. Future Oncol. 2019 Sep;15(25):2915–2931. doi: 10.2217/fon-2018-0876
   PubMed Web of Science ®Google Scholar
• Shiono A, Kaira K, Mouri A, et al. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients. Thorac Cancer. 2019;10(4):775–781. doi: 10.1111/1759-7714.12998
   PubMed Web of Science ®Google Scholar
• Corral J, Majem M, Rodríguez-Abreu D, et al. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. Clin Transl Oncol. 2019 Sep 1;21(9):1270–1279. doi: 10.1007/s12094-019-02053-7
   PubMed Web of Science ®Google Scholar
• Brueckl WM, Reck M, Rittmeyer A, et al. Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Transl Lung Cancer Res. 2021 Jul;10(7):3093–3105. doi: 10.21037/tlcr-21-197
   PubMed Web of Science ®Google Scholar
• Grohe C, Wehler TC, Henschke S, et al. 1143P - Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy. ESMO Congress; Paris; 2022.
   Google Scholar
• Grohé C, Blau W, Gleiber W, et al. Real-world efficacy of nintedanib plus docetaxel after progression on immune checkpoint inhibitors: results from the ongoing, non-interventional VARGADO study. Clin Oncol R Coll Radiol G B. 2022 Jul;34(7):459–468. doi: 10.1016/j.clon.2021.12.010
   PubMed Web of Science ®Google Scholar
• Levra MG, Cotté FE, Corre R, et al. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer. 2020 Feb 1;140:99–106. doi: 10.1016/j.lungcan.2019.12.017
   PubMed Web of Science ®Google Scholar
• Gobbini E, Toffart AC, Pérol M, et al. Immune checkpoint inhibitors rechallenge efficacy in non–small-Cell lung cancer patients. Clin Lung Cancer. 2020 Sep 1;21(5):e497–510. doi: 10.1016/j.cllc.2020.04.013
   PubMed Web of Science ®Google Scholar
• Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of retreating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res. 2018 Sep;6(9):1093–1099. doi: 10.1158/2326-6066.CIR-17-0755
   PubMed Web of Science ®Google Scholar
• Metro G, Signorelli D. Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions? Lung Cancer Manag. 2019;8(4):LMT18. doi:10.2217/lmt-2019-0012
   Web of Science ®Google Scholar
• Herbst RS, Garon EB, Kim DW, et al. Long-term outcomes and retreatment among patients with Previously treated, programmed death-ligand 1‒positive, advanced non‒small-Cell lung cancer in the KEYNOTE-010 study. J Clin Oncol. 2020 May 10;38(14):1580–1590. doi: 10.1200/JCO.19.02446
   PubMed Web of Science ®Google Scholar
• Sheth S, Gao C, Mueller N, et al. Durvalumab activity in previously treated patients who stopped durvalumab without disease progression. J Immunother Cancer. 2020 Aug 1;8(2):e000650. doi: 10.1136/jitc-2020-000650
   PubMed Web of Science ®Google Scholar
• Katayama Y, Shimamoto T, Yamada T, et al. Retrospective efficacy analysis of immune checkpoint inhibitor rechallenge in patients with non-small cell lung cancer. J Clin Med. 2019 Dec 31;9(1):102. doi: 10.3390/jcm9010102
   PubMed Web of Science ®Google Scholar
• Ponce Aix S, Carcereny Costa E, Bosch-Barrera J, et al. 160P - Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): a preliminary report of the REPLAY phase II trial - cohort I. ESMO Immuno-Oncology Congress 2021.
   Google Scholar
• Franceschini D, De Rose F, Cozzi S, et al. The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: state of the art. Crit Rev Oncol Hematol. 2020 Apr 1;148:102894. doi: 10.1016/j.critrevonc.2020.102894
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2018 Oct 1;29:iv192–237. doi: 10.1093/annonc/mdy275
   PubMedGoogle Scholar
• Jairam V, Park HS, Decker RH. Local ablative therapies for oligometastatic and oligoprogressive non–small cell lung cancer. Cancer J. 2020 Apr;26(2):129–136. doi: 10.1097/PPO.0000000000000433
   PubMed Web of Science ®Google Scholar
• Patel RR, Verma V, Barsoumian HB, et al. Use of multi-site radiation therapy for systemic disease control. Int J Radiat Oncol. 2021 Feb 1;109(2):352–364. doi: 10.1016/j.ijrobp.2020.08.025
   PubMed Web of Science ®Google Scholar
• Kaur P, Asea A. Radiation-induced effects and the immune system in cancer. Front Oncol. 2012;2:191. doi: 10.3389/fonc.2012.00191
   PubMedGoogle Scholar
• Daly ME, Monjazeb AM, Kelly K. Clinical trials integrating immunotherapy and radiation for non–small-Cell lung cancer. J Thorac Oncol. 2015 Dec 1;10(12):1685–1693. doi: 10.1097/JTO.0000000000000686
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, et al. Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014 Feb 2;124(2):687. doi: 10.1172/JCI67313
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Wurtz A, Goldberg SB, et al. Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non–small cell lung cancer. J Thorac Oncol. 2018 Jun 1;13(6):831–839. doi: 10.1016/j.jtho.2018.03.008
   PubMed Web of Science ®Google Scholar
• Wang Z, Wei L, Li J, et al. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2021 Dec;10(12):4368–4379. doi: 10.21037/tlcr-21-682
   PubMed Web of Science ®Google Scholar
• Fiorica F, Tebano U, Gabbani M, et al. Beyond abscopal effect: a meta-analysis of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancer. Cancers. 2021 May 13;13(10):2352. doi: 10.3390/cancers13102352
   PubMed Web of Science ®Google Scholar
• Bates JE, Morris CG, Milano MT, et al. Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: an analysis of the national cancer database. Radiother Oncol. 2019 Sep 1;138:75–79. doi: 10.1016/j.radonc.2019.06.004
   PubMed Web of Science ®Google Scholar
• Foster CC, Sher DJ, Rusthoven CG, et al. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a national cancer database analysis. Radiat Oncol. 2019 Jan 28;14(1):18. doi: 10.1186/s13014-019-1222-3
   PubMedGoogle Scholar
• Bahce I, Schneiders FL, Hashemi S, et al. 1020P - Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: the RECLAIM study. ESMO Congress; Paris; 2022.
   Google Scholar
• Fares CM, Van Allen EM, Drake CG, et al. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book. 2019 May;39(39):147–164. doi: 10.1200/EDBK_240837
   PubMedGoogle Scholar
• Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020 Jun;30(6):507–519. doi: 10.1038/s41422-020-0337-2
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Demaria S, Rodriguez-Ruiz ME, et al. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res. 2016 Apr 14;22(8):1845–1855. doi: 10.1158/1078-0432.CCR-16-0049
   PubMed Web of Science ®Google Scholar
• Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020 Jan;20(1):25–39. doi: 10.1038/s41577-019-0218-4
   PubMed Web of Science ®Google Scholar
• Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019 Nov 6;18(1):155. doi: 10.1186/s12943-019-1091-2
   PubMed Web of Science ®Google Scholar
• Leighl NB, Redman MW, Rizvi N, et al. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (lung-MAP substudy S1400F, NCT03373760). J Immunother Cancer. 2021 Aug 24;9(8):e002973. doi: 10.1136/jitc-2021-002973
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010 Sep 27;207(10):2187–2194. doi: 10.1084/jem.20100643
   PubMed Web of Science ®Google Scholar
• Falchook GS, Ribas A, Davar D, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER). ASCO Annual Metting 2022.
   Google Scholar
• Curigliano G, Gelderblom H, Mach N, et al. Phase I/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2021 Jul 1;27(13):3620–3629. doi: 10.1158/1078-0432.CCR-20-4746
   Google Scholar
• Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016 Apr 14;22(8):1865–1874. doi: 10.1158/1078-0432.CCR-15-1507
   PubMed Web of Science ®Google Scholar
• Felip E, Majem M, Doger B, et al. A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: updated results from a PD-L1 unselected population. J Clin Oncol. 2022 Jun;40(16_suppl):9003–9003. doi: 10.1200/JCO.2022.40.16_suppl.9003
   Web of Science ®Google Scholar
• Schöffski P, Tan DSW, Martín M, et al. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022 Feb 25;10(2):e003776. doi: 10.1136/jitc-2021-003776
   PubMed Web of Science ®Google Scholar
• Passiglia F, Reale ML, Cetoretta V, et al. Immune-checkpoint inhibitors combinations in metastatic NSCLC: new options on the horizon. Immunotargets Ther. 2021 Jan 1;10:9–26. doi: 10.2147/ITT.S253581
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Niu J, Kim DW, et al. 1400P vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC. Ann Oncol. 2020 Sep 1;31:S887. doi: 10.1016/j.annonc.2020.08.1714
   Web of Science ®Google Scholar
• Radhakrishnan V, Banavali S, Gupta S, et al. 1209P - Excellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1. Ann Oncol. 2019 Oct 1;30:v494. doi: 10.1093/annonc/mdz253.035
   PubMed Web of Science ®Google Scholar
• Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov. 2013 Feb;12(2):130–146. doi: 10.1038/nrd3877
   PubMed Web of Science ®Google Scholar
• Zhou F, Qiao M, Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol. 2021 Feb;18(2):279–293. doi: 10.1038/s41423-020-00577-5
   PubMed Web of Science ®Google Scholar
• Mayes PA, Hance KW, Hoos A. The promise and challenges of immune agonist antibody development in cancer. Nat Rev Drug Discov. 2018 Jul;17(7):509–527. doi: 10.1038/nrd.2018.75
   PubMed Web of Science ®Google Scholar
• Grilley-Olson JE, Curti BD, Smith DC, et al. SEA-CD40, a non-fucosylated CD40 agonist: interim results from a phase 1 study in advanced solid tumors. J Clin Oncol. 2018 May 20;36(15_suppl):3093–3093. doi: 10.1200/JCO.2018.36.15_suppl.3093
   Web of Science ®Google Scholar
• Berraondo P, Sanmamed MF, Ochoa MC, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019 Jan 8;120(1):6–15. doi: 10.1038/s41416-018-0328-y
   PubMed Web of Science ®Google Scholar
• Wrangle JM, Awad MM, Badin FB, et al. Preliminary data from QUILT 3.055: a phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI). J Clin Oncol. 2021 May 20;39(15_suppl):2596–2596. doi: 10.1200/JCO.2021.39.15_suppl.2596
   Web of Science ®Google Scholar
• Charych DH, Hoch U, Langowski JL, et al. NKTR-214, an engineered Cytokine with Biased IL2 receptor Binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016 Jan 31;22(3):680–690. doi: 10.1158/1078-0432.CCR-15-1631
   PubMed Web of Science ®Google Scholar
• Sharma M, Khong H, Fa’ak F, et al. Bempegaldesleukin selectively depletes intratumoral tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661. doi: 10.1038/s41467-020-14471-1
   PubMed Web of Science ®Google Scholar
• Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018 May;15(5):310–324. doi: 10.1038/nrclinonc.2018.9
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Redman MW, Dragnev KH, et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non–small-Cell lung cancer Previously treated with immunotherapy—lung-MAP S1800A. J Clin Oncol. 2022 Jul 20;40(21):2295–2306. doi: 10.1200/JCO.22.00912
   PubMed Web of Science ®Google Scholar
• Reckamp K, Redman MW, Dragnev K, et al. 1047P - Lung-MAP S1800A: exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI. ESMO Congress; Paris; 2022.
   Google Scholar
• Brose MS, Vogelzang NJ, DiSimone C, et al. A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer. J Clin Oncol. 2019 Mar 10;37(8_suppl):16–16. doi: 10.1200/JCO.2019.37.8_suppl.16
   Web of Science ®Google Scholar
• Leighl NB, Hui R, Rodríguez-Abreu D, et al. Abstract CT289: pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic non-small-cell lung cancer (NSCLC) and PD after platinum-doublet chemotherapy and immunotherapy: phase 3, randomized, open-label LEAP-008 trial. Cancer Res. 2020 Aug 15;80(16_Supplement):CT289. doi: 10.1158/1538-7445.AM2020-CT289
   Google Scholar
• Leal TA, Berz D, Rybkin I, et al. 43P MRTX-500: phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy. Ann Oncol. 2022 Mar 1;33:S19–20. doi: 10.1016/j.annonc.2022.01.052
   Web of Science ®Google Scholar
• Neal JW, Santoro A, Viteri S, et al. Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): results from cohorts 7 and 20 of the COSMIC-021 study. J Clin Oncol. 2022 Jun;40(16_suppl):9005–9005. doi: 10.1200/JCO.2022.40.16_suppl.9005
   Web of Science ®Google Scholar
• Chabanon RM, Rouanne M, Lord CJ, et al. Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nat Rev Cancer. 2021 Nov;21(11):701–717. doi: 10.1038/s41568-021-00386-6
   PubMed Web of Science ®Google Scholar
• Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol. 2015;15(12):760–770. doi: 10.1038/nri3921
   PubMed Web of Science ®Google Scholar
• Corte CMD, Sen T, Gay CM, et al. STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2020 May;15(5):777–791. doi: 10.1016/j.jtho.2020.01.009
   Google Scholar
• Della Corte CM, LA B. Evading the STING: LKB1 loss leads to STING silencing and immune escape in KRAS-mutant lung cancers. Cancer Discov. 2019 Jan;9(1):16–18. doi: 10.1158/2159-8290.CD-18-1286
   PubMed Web of Science ®Google Scholar
• Passiglia F, Reale ML, Cetoretta V, et al. Repositioning PARP inhibitors in the treatment of thoracic malignancies. Cancer Treat Rev .Internet. 2021 Sep 1 cited 2022 Sep 22; 99:102256. doi: 10.1016/j.ctrv.2021.102256
   PubMed Web of Science ®Google Scholar
• Besse B, Awad MM, Forde PM, et al. OA15.05 HUDSON: an open-label, multi-drug, biomarker-directed phase 2 study in NSCLC patients who progressed on anti-PD-(L)1 therapy. J Thorac Oncol. 2022 Sep 1;17(9, Supplement):S41–2. doi: 10.1016/j.jtho.2022.07.074
   Web of Science ®Google Scholar
• Marks S, Naidoo J. Antibody drug conjugates in non-small cell lung cancer: an emerging therapeutic approach. Lung Cancer. 2022 Jan 1;163:59–68. doi: 10.1016/j.lungcan.2021.11.016
   PubMed Web of Science ®Google Scholar
• Shaffer C. Trop2 deal heats up antibody–drug conjugate space in cancer. Nat Biotechnol. 2021 Feb 1;39(2):128–130. doi: 10.1038/s41587-021-00824-8
   PubMed Web of Science ®Google Scholar
• Okajima D, Yasuda S, Maejima T, et al. Datopotamab Deruxtecan, a novel TROP2-directed antibody–drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021 Dec 1;20(12):2329–2340. doi: 10.1158/1535-7163.MCT-21-0206
   PubMed Web of Science ®Google Scholar
• Spira A, Lisberg A, Sands J, et al. OA03.03 Datopotamab Deruxtecan (dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01 phase 1 study. J Thorac Oncol. 2021 Mar 1;16(3):S106–7. doi: 10.1016/j.jtho.2021.01.280
   Web of Science ®Google Scholar
• Yoh K, Goto Y, Thomas M, et al. A randomized, phase 3 study of datopotamab deruxtecan (dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01). J Clin Oncol. 2021 May 20;39(15_suppl):TPS9127–TPS9127. doi: 10.1200/JCO.2021.39.15_suppl.TPS9127
   Web of Science ®Google Scholar
• Levy B, Paz-Ares L, Rixe O, et al. MA13.07 TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. J Thorac Oncol. 2022 Sep 1;17(9):S91. doi: 10.1016/j.jtho.2022.07.152
   Web of Science ®Google Scholar
• Levy BP, Felip E, Reck M, et al. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol. 2023 Jul;19(21):1461–1472. doi: 10.2217/fon-2023-0230
   PubMed Web of Science ®Google Scholar
• Maitland ML, Sachdev JC, Sharma MR, et al. First-in-human study of PF-06647020 (Cofetuzumab Pelidotin), an antibody–drug conjugate targeting protein tyrosine kinase 7, in advanced solid tumors. Clin Cancer Res. 2021 Aug 15;27(16):4511–4520. doi: 10.1158/1078-0432.CCR-20-3757
   PubMed Web of Science ®Google Scholar
• Zhang X, Han X, Zuo P, et al. CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration. J Int Med Res. 2020 Sep 1;48(9):0300060520959478. doi: 10.1177/0300060520959478
   PubMed Web of Science ®Google Scholar
• Garassino MC, Reznick D, Liu SY, et al. EVOKE-01: a phase 3 study of sacituzumab govitecan (SG) versus docetaxel in patients with non–small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2022 Jun;40(16_suppl):TPS9149–TPS9149. doi: 10.1200/JCO.2022.40.16_suppl.TPS9149
   Web of Science ®Google Scholar
• Heist RS, Guarino MJ, Masters G, et al. Therapy of advanced non–small-Cell lung cancer with an SN-38-Anti-Trop-2 drug conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017 Aug 20;35(24):2790–2797. doi: 10.1200/JCO.2016.72.1894
   PubMed Web of Science ®Google Scholar
• Ghosn M, Tselikas L, Champiat S, et al. Intratumoral immunotherapy: is it ready for prime time? Curr Oncol Rep. 2023 Aug 1;25(8):857–867. doi: 10.1007/s11912-023-01422-4
   PubMed Web of Science ®Google Scholar
• Melero I, Castanon E, Alvarez M, et al. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol. 2021;18(9):558–576. doi: 10.1038/s41571-021-00507-y
   PubMed Web of Science ®Google Scholar
• Lee JM, Lee MH, Garon EB, et al. Phase I trial of intratumoral injection of CCL21 gene modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T cell infiltration. Clin Cancer Res Off J Am Assoc Cancer Res. 2017 Aug 15;23(16):4556–4568. doi: 10.1158/1078-0432.CCR-16-2821
   Google Scholar
• Hirsh V, Paz-Ares L, Boyer M, et al. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non–small-Cell lung cancer. J Clin Oncol. 2011 Jul;29(19):2667–2674. doi: 10.1200/JCO.2010.32.8971
   PubMed Web of Science ®Google Scholar
• Li Z, Feiyue Z, Gaofeng L, et al. Lung cancer and oncolytic virotherapy——enemy’s enemy. Transl Oncol. 2022 Oct 14;27:101563. doi: 10.1016/j.tranon.2022.101563
   PubMed Web of Science ®Google Scholar
• Bendell J, Bauer T, Patel M, et al. Abstract CT026: evidence of immune activation in the first-in-human phase ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors. Cancer Res. 2019 Jul 1;79(13_Supplement):CT026. doi: 10.1158/1538-7445.AM2019-CT026
   Web of Science ®Google Scholar
• Willingham SB, Hotson AN, Miller RA. Targeting the A2AR in cancer; early lessons from the clinic. Curr Opin Pharmacol. 2020 Aug 1;53:126–133. doi: 10.1016/j.coph.2020.08.003
   PubMed Web of Science ®Google Scholar
• Chiappori AA, Creelan B, Tanvetyanon T, et al. Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2022 Jun 1;28(11):2313–2320. doi: 10.1158/1078-0432.CCR-21-2742
   Google Scholar
• Crisafulli G, Sartore-Bianchi A, Lazzari L, et al. Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discov. candisc.2022 May 6;1434:2021.
   Google Scholar